Skip To Main Content
Del Vecchio L on Muck Rack

Del Vecchio L

As seen in: Oxford Academic, Oxford University Press (OUP)
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Del Vecchio L’s profile

Articles by Del Vecchio L

Hypoxia-inducible factor prolyl hydroxylase inhibitors for anaemia in chronic kidney disease: a clinical practice document by the European Renal Best Practice board of the European Renal Association

|
By Del Vecchio, Del Vecchio L
| Oxford Academic Verified
EPIDEMIOLOGY AND OUTCOMES OF ANAEMIA IN THE CHRONIC KIDNEY DISEASE (CKD) POPULATION Anaemia is a clinical hallmark of CKD and its prevalence and severity increases with progression of CKD [1–3]. It is twice as prevalent in patients with CKD compared with the general population [1] and is a substantial healthcare burden associated with increased healthcare resource utilization [4–6].
Open in Who Shared Issue with article?

Cardio-renoprotective effects of SGLT2 inhibitors-the role of anaemia correction

|
By Del Vecchio, Del Vecchio L
| Oxford University Press (OUP)
Sodium/glucose co-transporter 2 inhibitors (SGLT2i) slow the progression of chronic kidney disease (CKD) and heart failure without the risk of concomitant hyperkalaemia and with a lower risk of developing acute kidney injury than renin–angiotensin system (RAS) inhibitors. Apart from their impressive cardio-renal protection, SGLT2i have several pleiotropic effects of interest to nephrologists, especially regarding one of the most common and important complications of CKD, anaemia.
Open in Who Shared View Duplicates (23) Issue with article?

A Peculiar CLL Case with Complex Chromosome 6 Rearrangements and Refinement of All Breakpoints at the Gene Level by Genomic Array: A Case Report

|
By Del Vecchio L
| ncbi.nlm.nih.gov
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Open in Who Shared View Duplicates (623) Issue with article?

Erythropoiesis stimulating agents and nephroprotection: is there any room for new trials?

|
By Del Vecchio L, Zuccalà A
| Oxford University Press (OUP)
The paper by Fliser et al. [1], which has been published in this issue of Nephrology Dialysis Transplantation, was aimed at assessing the effect of a low dose of the continuous erythropoiesis receptor activator (CERA) on the rate of decline of kidney function in patients with moderate chronic kidney disease (CKD) [estimated glomerular filtration rate (eGFR) between 30 and 59 mL/min/1.73 m2].
Open in Who Shared Issue with article?
Show More